📋 Tender Overview
From January to November 2024, more than S/ 1,500 million were allocated for the purchase of medicines in all service and care networks. Social Health Insurance (EsSalud) establishments maintain a 96.38% supply of medicines nationwide, ensuring availability for more than a month, which allows guaranteeing continuity in the treatment of insured and beneficiaries, after care in outpatient, hospitalization and emergency services.
According to the latest report from the EsSalud Strategic Goods Supply Center (CEABE), for the remaining 3.62% (with coverage for less than a month), purchasing processes are being carried out to ensure a continuous supply.
Thus, of the 691 medicines purchased, the majority have a stock of between two and four months. Only 25 medicines have a stock of less than 1 month, however, periodic purchases are being managed to guarantee care for insured people in hospitals in Lima and the interior of the country.
From January to November 2024, EsSalud allocated more than S/ 1,503 million in the acquisition of medicines. Among the highlighted items are oncological medicines (S/ 119 million), treatments for HIV (S/ 34 million), TB (S/ 29 million), and medicines for other vital treatments (S/ 125 million).
Likewise, coverage of 20 high-cost medicines (HCMs) represented an investment of more than S/ 100 million.
Among the networks with the greatest investment in medicines are:
Rebagliati: S/ 364 million,
Almenara: S/ 223 million
Sabogal: S/ 175 million
Arequipa: S/ 141 million
La Libertad: S/ 88 million
Lambayeque: S/ 77 million
Under the leadership of the executive president of EsSalud, Dr. Maria Elena Aguilar Del Aguila, the current administration works constantly to guarantee the timely delivery of medicines and medical supplies, strengthening care for insured people in all hospitals in the country.
